比梅基祖马布用于治疗牛皮关节炎
1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.
Expert review of clinical immunology
|November 1, 2023
概括
比梅基祖马布是一种选择性IL-17F和IL-17A抑制剂,在治疗牛皮关节炎 (PsA) 中表现出快速和持续的疗效. 虽然一般耐受良好,但观察到局部的真菌感染.
科学领域:
- 免疫学和风湿病学
- 药理学和药物开发领域
背景情况:
- 干白素 (IL) -17A和IL -17F是关键的促炎细胞因子,涉及到牛皮病的发病因子.
- 牛皮关节炎 (PsA) 是一种慢性炎症状况,影响关节和皮肤.
- 比梅基祖马布是一种新型单克隆抗体,针对IL-17A和IL-17F.
研究的目的:
- 批判性地评估临床试验数据,以评估比梅奇祖马布在治疗精神病的疗效和安全性.
- 评估PsA患者的比梅奇祖马布的治疗反应和耐受性.
主要方法:
- 进行了一项文献搜索,以确定PSA中比梅奇祖马布的相关临床试验.
- 鉴定的试验在有效性和安全性方面得到了批判性评估.
主要成果:
- 比梅基祖马布在PsA中表现出跨多种疾病领域的快速和持续的治疗反应.
- 高效率水平保持在152周 (第二阶段b) 和52周 (第三阶段).
- 比梅基祖马布一般耐受性良好,局部真菌感染的轻度至中度增加.
结论:
- 比梅基祖马布在患有牛皮关节炎的患者中具有显著和持久的疗效.
- 安全性概况通常是有利的,尽管真菌感染需要监测.
- 需要进一步的长期研究和现实世界的数据来将比梅奇祖马布置于现有的PsA治疗中.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K


